Metastatic NSCLC: 3 positive endpoints for 1L therapy
- FLASCO
- March 10, 2015
- Drugs
- No Comments
Metastatic NSCLC: 3 positive endpoints for 1L therapy Read More please click here
FDA Approves Palbociclib for Metastatic Breast Cancer
- FLASCO
- March 10, 2015
- Drugs
- No Comments
FDA Approves Palbociclib for Metastatic Breast Cancer The U. S. Food and Drug Administration granted accelerated approval to palbociclib (IBRANCE®, Pfizer, Inc.) for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast for their metastatic disease. Read more
Provenge
- FLASCO
- March 10, 2015
- Drugs
- No Comments
Provenge NCCN recently updated their Prostate Cancer treatment guidelines based on guidance from a panel of academic Oncologists and Urologists and patient advocacy leaders from around the country. The updated NCCN guidelines elevate PROVENGE to a more prominent position, recommending its use as the first treatment with an overall survival advantage for men with asymptomatic…
Trastuzumab Emtansine (T-DM1)*
- FLASCO
- March 10, 2015
- Drugs
- No Comments
Trastuzumab Emtansine (T-DM1)* ASCO® Clinical Oncology Practice Guidelines recommend trastuzumab emtansine (T-DM1)* as second-line therapy for advanced HER2+ breast cancer1,2. For complete information, please click here.
KEYTRUDA Will Now Be Supplied as a 100 mg/4 mL (25 mg/mL) Solution in a Single-Use Vial
- FLASCO
- March 10, 2015
- Drugs
- No Comments
KEYTRUDA Will Now Be Supplied as a 100 mg/4 mL (25 mg/mL) Solution in a Single-Use Vial Merck is pleased to announce the availability of a liquid formulation of KEYTRUDA. Merck expects to make this product available on or after February 16, 2015. Check with your authorized distributor for details. This 100-mg liquid vial will…
IMBRUVICA® (ibrutinib)
- FLASCO
- March 10, 2015
- Drugs
- No Comments
IMBRUVICA® (ibrutinib) Pharmacyclics, Inc. and Janssen Biotech, Inc., are pleased to announce that, as of January 29, 2015, IMBRUVICA® (ibrutinib) has been granted regular approval by the FDA for use in patients with Waldenström’s Macroglobulinemia (WM). For updated information, please see accompanying Full Prescribing Information
FDA Approves Lanreotide For Treatment of GEP-NETs
- FLASCO
- March 10, 2015
- Drugs
- No Comments
FDA Approves Lanreotide For Treatment of GEP-NETs The U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. Lanreotide was previously approved for the long-term treatment of acromegalic patients who…
FDA Approves BLINCYTOTM (blinatumomab)
- FLASCO
- March 10, 2015
- Drugs
- No Comments
FDA Approves BLINCYTOTM (blinatumomab) the U.S. Food and Drug Administration approved BLINCYTOTM (blinatumomab) for injection, for intravenous use. Trade Name NDC* Pack Size WAC BLINCYTOTM 55513-0160-01 35 mcg lyophilized powder, single use vial IVSS (IV Solution Stabilizer) 10 mL single use vial $ 3178.57 *Note that the product’s NDC code has been “zero-filled” to…
FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer (
- FLASCO
- March 10, 2015
- Drugs
- No Comments
FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer The FDA approval of olaparib occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian cancer. To read more…
FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer
- FLASCO
- March 10, 2015
- Drugs
- No Comments
FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer The U.S. Food and Drug Administration (FDA) today granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three or more prior lines…
FDA Approves Gazyva® (Obinutuzumab)
- FLASCO
- March 10, 2015
- Drugs
- No Comments
FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chronic Lymphocytic Leukemia Genentech, a member of the Roche Group, announced that the FDA approved a supplemental biologics license application (sBLA) for Gazyva in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL). read corporate press release »
Keytruda Code Update
- FLASCO
- March 10, 2015
- Drugs
- No Comments
Keytruda Code Update Keytruda (Merck) has been assigned a Level II HCPCS C code, effective 1/1/2015. This code applies to Medicare hospital outpatient claims for dates of service on or after 1/1/2015. HCPCS Code : C9027 For more information click here.
FDA Approves Opdivo for Advanced Melanoma
- FLASCO
- March 10, 2015
- Drugs
- No Comments
FDA Approves Opdivo for Advanced Melanoma The U.S. Food and Drug Administration today granted accelerated approval to Opdivo (nivolumab), a new treatment for patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugs. Read press release Click to read Opdivo Announcement For more information Opdivo
FLASCO Foundation Inc. Holds It’s First Patient Advocacy Program!
- FLASCO
- February 25, 2015
- News
- No Comments
The Goal of the FLASCO Foundation, Inc., Outreach program is to bring together cancer patients, cancer survivors, caregivers, oncology experts and corporate supporters together to learn and exchange information on various types of cancer. This project was the dream of Past President Gerald Robbins, MD. This was one of his main initiatives and it was…
